Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a …
Background It has been shown that a subgroup of patients with differentiated thyroid cancer
(DTC) and medullary thyroid carcinoma (MTC) would progress to advanced stages of thyroid …
(DTC) and medullary thyroid carcinoma (MTC) would progress to advanced stages of thyroid …
Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review
S Chen, A Flower, A Ritchie, J Liu, A Molassiotis, H Yu… - Lung cancer, 2010 - Elsevier
BACKGROUND: Non-small cell lung cancer (NSCLC) remains a major global health
problem because of its prevalence and poor prognosis. Treatment options are limited and …
problem because of its prevalence and poor prognosis. Treatment options are limited and …
Somatostatin receptor–targeted radiopeptide therapy in treatment-refractory meningioma: Individual patient data meta-analysis
Somatostatin receptor (SSTR)–targeted peptide receptor radionuclide therapy (PRRT)
represents a promising approach for treatment-refractory meningiomas. Methods: We …
represents a promising approach for treatment-refractory meningiomas. Methods: We …
[HTML][HTML] The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer
G Kasymjanova, N MacDonald, JS Agulnik… - Current …, 2010 - ncbi.nlm.nih.gov
Background Accurate prediction of outcome in advanced non-small-cell lung cancer (nsclc)
remains challenging. Even within the same stage and treatment group, survival and …
remains challenging. Even within the same stage and treatment group, survival and …
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFα to cancer vasculature
MC Paoloni, A Tandle, C Mazcko, E Hanna, S Kachala… - PloS one, 2009 - journals.plos.org
Background Under the direction and sponsorship of the National Cancer Institute, we report
on the first pre-clinical trial of the Comparative Oncology Trials Consortium (COTC). The …
on the first pre-clinical trial of the Comparative Oncology Trials Consortium (COTC). The …
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)
S Zovato, A Kumanova, S Dematte… - Hormone and …, 2012 - thieme-connect.com
Paragangliomas (PGLs) are neuroendocrine tumors that arise embryologically from the
neural crest. Sympathetic PGLs can be located in the thoracic-abdominal region while …
neural crest. Sympathetic PGLs can be located in the thoracic-abdominal region while …
Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors
Aim To compare response assessment according to the WHO, RECIST 1.1, EORTC, and
PERCIST criteria in patients diagnosed with malignant solid tumors and who had received …
PERCIST criteria in patients diagnosed with malignant solid tumors and who had received …
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
J Nemunaitis, G Clayman, SS Agarwala… - Clinical cancer …, 2009 - AACR
Purpose: Most recurrent squamous cell carcinomas of the head and neck have a
dysfunctional p53 tumor suppressor pathway contributing to treatment resistance. We …
dysfunctional p53 tumor suppressor pathway contributing to treatment resistance. We …
Radionuclide therapy in neuroendocrine tumours: a systematic review
The purpose of this systematic review was to investigate the effects of therapeutic
radiopharmaceuticals in patients with different types of advanced neuroendocrine tumour …
radiopharmaceuticals in patients with different types of advanced neuroendocrine tumour …
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous …
MW Saif, K Kaley, M Brennan, MC Garcon… - JOP. Journal of the …, 2013 - serena.unina.it
Context Pancreatic neuroendocrine tumors (pNETs) are notoriously resistant to currently
available chemotherapy agents. Preclinical data has suggested synergy between …
available chemotherapy agents. Preclinical data has suggested synergy between …